Rhythm Pharmaceuticals (RYTM) Issues Earnings Results, Beats Expectations By $0.14 EPS

Rhythm Pharmaceuticals (NASDAQ:RYTM) issued its earnings results on Monday. The company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.14, Bloomberg Earnings reports.

Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) traded down $0.15 during mid-day trading on Tuesday, hitting $27.19. The company’s stock had a trading volume of 3,716 shares, compared to its average volume of 67,330. Rhythm Pharmaceuticals has a 52-week low of $21.38 and a 52-week high of $33.81.

A number of brokerages have weighed in on RYTM. BidaskClub raised Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, February 26th. Finally, Cowen reaffirmed a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Rhythm Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $31.25.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/03/13/rhythm-pharmaceuticals-rytm-issues-earnings-results-beats-expectations-by-0-14-eps.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply